Abstract
Persistent neuroinflammation is now recognized as a chief pathological component of practically all neurodegenerative diseases. Neuroinflammation in the central nervous system (CNS), is accompanied with immune responses of glial cells. Glial cells respond to pathological stimuli through antigen presentation, and cytokine and chemokine signaling. Therefore, limiting CNS inflammation represents prospective therapeutic approach in diseases like Alzheimer’s, amyotrophic lateral sclerosis, Parkinson’s, ischemia, various psychiatric disorders and Multiple sclerosis (MS). As a complex disease, MS is characterized by neuroinflamation, demyelination and sequential axonal loss. Due to unknown etiology and the heterogeneous presentation of the disease, MS is hard to treat and the search for potential therapeutics is wide and meticulous. However, finding a proper antineuroinflammatory drug may bring an advance in selecting novel treatment regimens of ample of neurodegenerative diseases and neurological disorders. The present review gives the overview of the existing and potential therapies in MS, aimed to modulate neuroinflammation and ensure neuroprotection.
Keywords: MS, EAE, neuroinflammation, therapies.
Current Pharmaceutical Design
Title:Multiple Sclerosis and Neuroinflammation: The Overview of Current and Prospective Therapies
Volume: 23 Issue: 5
Author(s): Ivana Bjelobaba, Danijela Savic and Irena Lavrnja
Affiliation:
Keywords: MS, EAE, neuroinflammation, therapies.
Abstract: Persistent neuroinflammation is now recognized as a chief pathological component of practically all neurodegenerative diseases. Neuroinflammation in the central nervous system (CNS), is accompanied with immune responses of glial cells. Glial cells respond to pathological stimuli through antigen presentation, and cytokine and chemokine signaling. Therefore, limiting CNS inflammation represents prospective therapeutic approach in diseases like Alzheimer’s, amyotrophic lateral sclerosis, Parkinson’s, ischemia, various psychiatric disorders and Multiple sclerosis (MS). As a complex disease, MS is characterized by neuroinflamation, demyelination and sequential axonal loss. Due to unknown etiology and the heterogeneous presentation of the disease, MS is hard to treat and the search for potential therapeutics is wide and meticulous. However, finding a proper antineuroinflammatory drug may bring an advance in selecting novel treatment regimens of ample of neurodegenerative diseases and neurological disorders. The present review gives the overview of the existing and potential therapies in MS, aimed to modulate neuroinflammation and ensure neuroprotection.
Export Options
About this article
Cite this article as:
Bjelobaba Ivana, Savic Danijela and Lavrnja Irena, Multiple Sclerosis and Neuroinflammation: The Overview of Current and Prospective Therapies, Current Pharmaceutical Design 2017; 23 (5) . https://dx.doi.org/10.2174/1381612822666161214153108
DOI https://dx.doi.org/10.2174/1381612822666161214153108 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Personalized Drug Discovery: HCA Approach Optimized for Rare Diseases at Tel Aviv University
Combinatorial Chemistry & High Throughput Screening Patent Selections:
Recent Patents on Regenerative Medicine Future Treatment for COPD: Targeting Oxidative Stress and its Related Signal
Recent Patents on Inflammation & Allergy Drug Discovery Genetic Predisposition to Parkinson’s Disease and Cancer
Current Cancer Drug Targets Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System
Current Pharmaceutical Design Editorial (Thematic Selection: Strategies of Current Drugs and Alternative Treatments for Neurodegenerative Diseases)
Current Neuropharmacology Autologous Mesenchymal Stem Cell Therapy in Progressive Multiple Sclerosis: An Open Label Study
Current Stem Cell Research & Therapy Involvement of Cytosolic Phospholipase A2, Calcium Independent Phospholipase A2 and Plasmalogen Selective Phospholipase A2 in Neurodegenerative and Neuropsychiatric Conditions
Current Medicinal Chemistry Meet the Editorial Board:
Current Topics in Medicinal Chemistry Identification of Molecular Targets Associated with Ethanol Toxicity and Implications in Drug Development
Current Pharmaceutical Design Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders
Current Nanoscience SUMOylation in Neurological Diseases
Current Molecular Medicine The Cannabinoids Switch of Oxidative Stress: A Double-Edged Sword
Mini-Reviews in Organic Chemistry The Co-Metabolism within the Gut-Brain Metabolic Interaction: Potential Targets for Drug Treatment and Design
CNS & Neurological Disorders - Drug Targets Stimuli-Responsive Nanocarriers for Drug Delivery to the Central Nervous System
Current Nanoscience Cytopathological Mechanisms in Mitochondrial Disease
Current Chemical Biology Cyclin-Dependent Kinase Inhibitors: Cancer Killers to Neuronal Guardians
Current Medicinal Chemistry Understanding Abnormal c-JNK/p38MAPK Signaling in Amyotrophic Lateral Sclerosis: Potential Drug Targets and Influences on Neurological Disorders
CNS & Neurological Disorders - Drug Targets Molecular Insights into Mechanisms of the Cell Death Program:Role in the Progression of Neurodegenerative Disorders
Current Alzheimer Research The Role of Calcium Stores in Apoptosis and Autophagy
Current Molecular Medicine